Neurotransmitters and CNS disease. Dementia

Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series.

Molecular psychiatry·2018

Psychiatric symptoms in patients with focal cortical degeneration.

Behavioural neurology·2014

Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial.

Revue neurologique·2013

Presymptomatic studies in genetic frontotemporal dementia.

Revue neurologique·2013

Measuring disease progression in frontotemporal lobar degeneration: a clinical and MRI study.

Neurology·2010

Memory complaints and increased rates of brain atrophy: risk factors for mild cognitive impairment and Alzheimer's disease.

International journal of geriatric psychiatry·2010

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

Lancet (London, England)·2026

Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial.

Lancet (London, England)·2026

Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.

Lancet (London, England)·2026

Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.

Lancet (London, England)·2026

AUT00206, a novel and selective Kv3.1/3.2 channel modulator, restores cognitive dysfunction and negative symptoms in an animal model for schizophrenia symptomatology.

Journal of psychopharmacology (Oxford, England)·2026

Hypernatremia as the Initial Presentation of Osmotic Demyelination Syndrome: A Rare Case with Favorable Neurological Outcome.

Case reports in neurology·2026

Calycosin attenuates LPS-induced microglia inflammatory responses and microglia-mediated synaptic impairment via modulation of TLR4/MyD88/NF-κB signaling pathway.

Frontiers in pharmacology·2026

Structure of NHE6 and its lipid-mediated interactions regulating endosomal pH.

Nature communications·2026

Trigeminal Nerve Electrical Stimulation Attenuates Hypoxic-Ischemic Brain Injury by Regulating GLT-1-mediated Endoplasmic Reticulum Stress.

Brain research bulletin·2026

Divergent cortical-subcortical intrinsic neural timescales in first-episode drug-naïve or minimally treated schizophrenia.

Asian journal of psychiatry·2026

Related Experiment Videos

Neurotransmitters and CNS disease. Dementia

Related Concept Videos

Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series.

Psychiatric symptoms in patients with focal cortical degeneration.

Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial.

Presymptomatic studies in genetic frontotemporal dementia.

Measuring disease progression in frontotemporal lobar degeneration: a clinical and MRI study.

Memory complaints and increased rates of brain atrophy: risk factors for mild cognitive impairment and Alzheimer's disease.

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial.

Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.

Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.

AUT00206, a novel and selective Kv3.1/3.2 channel modulator, restores cognitive dysfunction and negative symptoms in an animal model for schizophrenia symptomatology.

Hypernatremia as the Initial Presentation of Osmotic Demyelination Syndrome: A Rare Case with Favorable Neurological Outcome.

Calycosin attenuates LPS-induced microglia inflammatory responses and microglia-mediated synaptic impairment via modulation of TLR4/MyD88/NF-κB signaling pathway.

Structure of NHE6 and its lipid-mediated interactions regulating endosomal pH.

Trigeminal Nerve Electrical Stimulation Attenuates Hypoxic-Ischemic Brain Injury by Regulating GLT-1-mediated Endoplasmic Reticulum Stress.

Divergent cortical-subcortical intrinsic neural timescales in first-episode drug-naïve or minimally treated schizophrenia.

Related Experiment Videos

Neurotransmitters and CNS disease. Dementia

Related Concept Videos

Related Articles